Pharmacogenetics and pharmacoepigenetics of gemcitabine
Por:
Candelaria M., De La Cruz-Hernández E., Pérez-Cárdenas E., Trejo-Becerril C., Gutiérrez-Hernández O., Duenas-Gonzalez, A
Publicada:
1 dic 2010
Resumen:
Gemcitabine (2',2'-difluoro 2'deoxycytidine, dFdC) is an analog of cytosine with distinctive pharmacological properties and a wide antitumor-activity spectrum. The pharmacological characteristics of gemcitabine are unique because two main classes of genes are essential for its antitumor effects: membrane transporter protein-coding genes, whose products are responsible for drug intracellular uptake, as well as enzyme-coding genes, which catalyze its activation and inactivation. The study of the pharmacogenetics and pharmacoepigenetics of these two gene classes is greatly required to optimize the drug's therapeutic use in cancer. This review aims to provide an update of genetic and epigenetic bases that may account for interindividual variation in therapeutic outcome exhibited by gemcitabine.
Filiaciones:
Candelaria M.:
Division of Clinical Research, Instituto Nacional de Cancerología (INCan), Mexico City, Mexico
De La Cruz-Hernández E.:
Division of Basic Research, Instituto Nacional de Cancerología (INCan), Mexico City, Mexico
Pérez-Cárdenas E.:
Division of Basic Research, Instituto Nacional de Cancerología (INCan), Mexico City, Mexico
Trejo-Becerril C.:
Division of Basic Research, Instituto Nacional de Cancerología (INCan), Mexico City, Mexico
Gutiérrez-Hernández O.:
Division of Basic Research, Instituto Nacional de Cancerología (INCan), Mexico City, Mexico
Duenas-Gonzalez, A:
Univ Nacl Autonoma Mexico, Inst Invest Biomed, Inst Nacl Cancerol, Unit Biomed Res Canc, Mexico City 04510, DF, Mexico
|